FDA approves X4 Pharmaceuticals’ pill for ultra-rare immunodeficiency disease Endpoints NewsFDA approves X4 Pharmaceuticals’ drug for ultra-rare WHIM syndrome The Boston GlobeUS FDA approves X4 Pharmaceuticals’ therapy for immunodeficiency disease ReutersX4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome Yahoo FinanceFDA Approves First Targeted Treatment for WHIM Syndrome BioSpace